Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEM 1003

Drug Profile

MEM 1003

Alternative Names: BAY Z 4406

Latest Information Update: 22 Mar 2010

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Memory Pharmaceuticals
  • Class Antidementias; Dihydropyridines; Neuroprotectants; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Bipolar disorders; Mild cognitive impairment; Vascular dementia

Most Recent Events

  • 07 Nov 2007 Pharmacodynamics data from a preclinical study in cognitive decline and Alzheimer's disease presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 18 Oct 2007 Final results from a phase IIa clinical trial in patients with Alzheimer's disease added to the adverse events and Alzheimier's Disease therapeutic trials sections
  • 11 Apr 2007 Memory Pharmaceuticals completes enrolment in its phase IIa trial for Alzheimer's Disease in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top